SEC Tracker
Get the app
AIBT · XBRL financial data

Aibotics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (AIBT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue——0000*2000*00
Gross profit——000—200—00
General and administrative165189*361391385497*532361480474*359414
Total operating expenses165189*361391385497*532361480474*359414
Operating income (loss)(165)(189)*(361)(391)(385)(497)*(529)(361)(480)(474)*(359)(414)
Interest expense143102*657975(6)*62701161*5947
Income tax expense (benefit)00*0000*0000*00
Net income (loss)(309)(291)*(426)(471)(460)(492)*(591)(486)(530)(608)*(418)(537)
  • † Share count changed about 7x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (AIBT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents317279370280202185157242230256289233
Inventory—————————04141
Total current assets317279371280203185157242241270331276
Property and equipment, net1000000——000
Total assets3182,2192,1451,8881,6431,4571,2641,1861,017875771550
Accrued liabilities—240295375450400462417180217879951
Total current liabilities2,0554,2484,5994,8135,0024,8525,1015,3944,9034,7945,0515,151
Total liabilities2,0554,2484,5994,8135,0024,8525,1015,3944,9034,8355,0515,151
Accumulated deficit(8,670)(8,961)(9,387)(9,858)(10,318)(10,809)(11,401)(11,887)(12,417)(13,025)(13,443)(13,980)
Total stockholders' equity(1,737)(2,028)(2,454)(2,925)(3,359)(3,395)(3,837)(4,208)(3,886)(3,960)(4,280)(4,602)
Total liabilities and equity3182,2192,1451,8881,6431,4571,2641,1861,017875771550
Common shares outstanding (cover page) thousands of shares14,89714,89714,89714,8975,99142,69146,244191,904440,613567,695681,986850,165
  • † Share count changed about 7x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (AIBT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(309)(291)*(426)(471)(460)(492)*(591)(486)(530)(608)*(418)(537)
Stock-based compensation0*(44)*——0*0*——————
Net cash from operating activities(22)*(38)*(74)(91)*(78)*(17)*(28)(165)*(179)*(87)*(36)(47)*
Net cash from investing activities0*0*00*0*—00*——00*
Proceeds from issuing common stock—————0*———112*——
Net cash from financing activities0*0*1650*0*0*0250*167*112*69(8)*
  • † Share count changed about 7x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Aibotics2330(47)*850.2M5.0 quarters 10-QJun 30, 2026
Agentix0not reported(26)40.1M0.0 quarters 10-QJun 30, 2026
Galera Therapeutics5,500not reported(875)160.4M6.3 quarters 10-QMar 31, 2026
ProtoKinetix1.1not reported0.6*411.6M— 10-KDec 31, 2025
Evofem Biosciences2852,633(3,140)*132.5M0.1 quarters 10-QJun 30, 2026
Regen BioPharma0.259(24)*1.7B0.0 quarters 10-QJun 30, 2026
Twinlab Consolidated Holdings13not reported(907)*259.1M0.0 quarters 10-KDec 31, 2024
Decoy Therapeutics8,289228(2,652)*655,1853.1 quarters 10-QJun 30, 2026
Nomad Power Solutions12,670not reported(1,612)*16.1M7.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.